Log in

Relevant bibliographies by topics / Equity lines / Journal articles

To see the other types of publications on this topic, follow the link: Equity lines.

Journal articles on the topic 'Equity lines'

Author: Grafiati

Published: 7 July 2024

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Equity lines.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Ebens, Allen J., Leanne Berry, Yung-Hsiang Chen, et al. "A Selective PIM Kinase Inhibitor Is Highly Active In Multiple Myeloma: The Biology of Single Agent and PI3K/AKT/mTOR Combination Activity." Blood 116, no. 21 (2010): 3001. http://dx.doi.org/10.1182/blood.v116.21.3001.3001.

Full text

Abstract:

Abstract Abstract 3001 PIM kinases co-regulate several important elements of the PI3K/AKT/mTOR pathway in myeloma cells (Munugalavadla V. et al., ASH 2010 submitted abstr.). In this study we show that pan-PIM inhibition suppresses growth in myeloma cell lines, xenografts, and primary patient samples, both as a single-agent as well acting synergistically in combination with PI3K, AKT, and mTOR inhibition. The PIM kinases are a family of 3 ser/thr growth factor- & cytokine-induced proteins hypothesized to have redundant survival and growth functions. Although PIM-1,2 have been noted as highl

APA, Harvard, Vancouver, ISO, and other styles

2

ANNAOUI, Ilias, and Pascal BARNETO. "The Determinants of Equity Lines Financing: An International Study." Bankers, Markets & Investors 171, no. 3 (2022): 43–50. http://dx.doi.org/10.54695/bmi.171.8461.

Full text

Abstract:

Equity lines financing allows companies to increase their capital by issuing shares in successive tranches, as and when required over an agreed period of time, in order to boost equity and cash flow. The purpose of this article is to examine the factors which inform the use of this method, considering the specific parameters of businesses using equity lines, as well as variables linked to the institutional and economic context. Employing a model based on the Generalized Method of Moments (GMM) technique, we studied 407 firms in 15 countries making using of equity lines Financing in the period

APA, Harvard, Vancouver, ISO, and other styles

3

Ngo, Anh, Oscar Varela, and Xie Feixue. "The effects of lines of credit on market timing and the underpricing of seasoned equity offerings." Review of Accounting and Finance 18, no. 1 (2019): 157–75. http://dx.doi.org/10.1108/raf-09-2016-0153.

Full text

Abstract:

PurposeThis paper aims to examine the effects of lines of credit on a firm’s market timing behavior and the pricing of its seasoned equity offerings (SEOs). It shows that firms with lines of credit are more likely to time the equity market and receive less underpricing for their SEOs. It also shows that the propensity of firms with lines of credit to time the market is particularly significant for financially unconstrained firms. The results are robust to different measures of market timing and financial constraint, and these fill the gap in the literature that, to the best of the authors’ kno

APA, Harvard, Vancouver, ISO, and other styles

4

Annaoui, Ilias, and Pascal Barneto. "Mécanismes de gouvernance et financement par Equity lines." Management & Avenir N° 135, no. 3 (2023): 37–60. http://dx.doi.org/10.3917/mav.135.0037.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Thomenius, Michael J., Jennifer Totman, Kat Cosmopoulos, et al. "Identification of a First-in-Class SETD2 Inhibitor That Shows Potent and Selective Anti-Proliferative Activity in t(4;14) Multiple Myeloma: T(4;14) Multiple Myeloma Cells Are Dependent on Both H3K36 Di and Tri-Methylation." Blood 132, Supplement 1 (2018): 3207. http://dx.doi.org/10.1182/blood-2018-99-110803.

Full text

Abstract:

Abstract t(4;14) chromosome translocations are found in 15% of newly diagnosed multiple myeloma (MM) cases and are associated with high risk. MM cells with t(4;14) over-express the histone methyltransferase (HMT), WHSC1/MMSET/NSD2, which leads to deregulation of gene expression due to increased di-methylation of Histone H3 at lysine 36 (H3K36me2). This activity has been shown to be essential for the survival of t(4;14) MM cells. In addition to WHSC1, another HMT, SETD2, has been shown to methylate H3K36. SETD2 is the only known enzyme capable of tri-methylation of H3K36 and has been reported t

APA, Harvard, Vancouver, ISO, and other styles

6

Munugalavadla, Veerendra, Leanne Berry, Yung-Hsiang Chen, et al. "A Selective PIM Kinase Inhibitor Is Highly Active In Multiple Myeloma: Mechanism of Action and Signal Transduction Studies." Blood 116, no. 21 (2010): 4084. http://dx.doi.org/10.1182/blood.v116.21.4084.4084.

Full text

Abstract:

Abstract Abstract 4084 Related work from our group has shown the therapeutic utility of PIM inhibition in multiple myeloma cell lines, xenografts, and primary patient samples (Ebens A. et al., ASH 2010 submitted abstr.). In this study we provide detailed mechanistic findings to show that PIM kinase inhibition co-regulates several important elements of the PI3K/AKT/mTOR pathway, resulting in significant synergy for combination drug treatments. The PIM kinases are a family of 3 ser/thr growth factor- & cytokine-induced proteins hypothesized to have redundant survival and growth functions. GN

APA, Harvard, Vancouver, ISO, and other styles

7

Dornan, David, Bart Burington, Peng Yue, et al. "CD40 Pathway Activation Status Predicts Response to CD40 Targeted Therapy in Diffuse Large b-Cell Lymphoma." Blood 114, no. 22 (2009): 2721. http://dx.doi.org/10.1182/blood.v114.22.2721.2721.

Full text

Abstract:

Abstract Abstract 2721 Poster Board II-697 The role of the CD40 pathway in B-cell cancers is rather enigmatic due to having polar opposite roles in tumor biology. Stimulation of the CD40 receptor can reduce cell viability of NHL cell lines and xenograft tumor models, whereas, in sharp contrast, constitutive CD40 stimulation can actually promote proliferation of NHL cell lines, as well as drive lymphomagenesis and transformation of primary B-cells. Therefore, targeting the CD40 pathway has been challenging due to a knowledge gap in understanding the factors that may dictate a pro- or anti-tumor

APA, Harvard, Vancouver, ISO, and other styles

8

Nadelson, Louis S., Rachelle G. Miller, Helen Hu, Na Mi Bang, and Brandy Walthall. "Is Equity on Their Mind? Documenting Teachers’ Education Equity Mindset." World Journal of Education 9, no. 5 (2019): 26. http://dx.doi.org/10.5430/wje.v9n5p26.

Full text

Abstract:

An education equity mindset is fundamental to assuring all students are supported to achieve to their highest capacity.We have identified six attributes of an educational equity mindset critical to assuring teachers’ practices andprofessional choices are aligned with meeting the needs of all students. In an effort to promote education equitymindset among teachers we determined there was a need to first empirically document the construct. We surveyed 452teachers in the southern region of the United States. Our results indicate that we effectively measured our definition ofeducation equity minds

APA, Harvard, Vancouver, ISO, and other styles

9

SALANDRO, DAN, and WILLIAM B. HARRISON. "Determinants of the Demand for Home Equity Credit Lines." Journal of Consumer Affairs 31, no. 2 (1997): 326–45. http://dx.doi.org/10.1111/j.1745-6606.1997.tb00394.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Liu, Yang, and J. Jimmy Yang. "Private debt, unused credit lines, and seasoned equity offerings." Quarterly Review of Economics and Finance 51, no. 4 (2011): 376–88. http://dx.doi.org/10.1016/j.qref.2011.07.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Eastman, Stephen, Christopher Shelton, Ira Gupta, Julie Krueger, Christina Blackwell, and Paul M. Bojczuk. "Synergistic Activity of Belantamab Mafodotin (anti-BCMA immuno-conjugate) with PF-03084014 (gamma-secretase inhibitor) in Bcma-Expressing Cancer Cell Lines." Blood 134, Supplement_1 (2019): 4401. http://dx.doi.org/10.1182/blood-2019-123705.

Full text

Abstract:

Multiple myeloma (MM) is a plasma cell malignancy characterized by clonal proliferation of plasma cells within the bone marrow. B cell maturation antigen (BCMA) is a cell-surface receptor required for the survival of plasma cells and is also ubiquitously expressed on MM cells. Belantamab Mafodotin (GSK2857916) is a humanised monoclonal anti-BCMA antibody, which is afucosylated and conjugated to the microtubule-disrupting agent monomethyl auristatin-F (MMAF). Upon binding to BCMA on the cell surface, belatamab mafodotin is rapidly internalised and the cytotoxic moiety (cys-mcMMAF) is released,

APA, Harvard, Vancouver, ISO, and other styles

12

Ulanet, Danielle, Victor Chubukov, John Coco, et al. "Hematologic Malignancies Exhibit Selective Vulnerability to Inhibition of De Novo Pyrimidine Biosynthesis By AG-636, a Novel Inhibitor of Dihydroorotate Dehydrogenase in Phase 1 Clinical Trials." Blood 134, Supplement_1 (2019): 1570. http://dx.doi.org/10.1182/blood-2019-123471.

Full text

Abstract:

Rapidly proliferating cells reprogram metabolism to support increased biosynthetic demands, a feature that can expose targetable vulnerabilities for therapeutic intervention. A chemical biology screen was performed in an effort to identify metabolic vulnerabilities in particular tumor subtypes, and revealed potent and selective activity of a novel dihydroorotate dehydrogenase (DHODH) inhibitor, AG-636, in cancer cell lines of hematologic origin. In contrast, cancer cell lines of solid tumor origin exhibited comparatively poor sensitivity. Evaluation of a lymphoma cell line panel demonstrated b

APA, Harvard, Vancouver, ISO, and other styles

13

Sampath, Deepak, Elizabeth Punnoose, Erwin R. Boghaert, et al. "Expression of Bcl-2 Pro-Survival Family Proteins Predicts Pharmacological Responses to ABT-199, a Novel and Selective Bcl-2 Antagonist, in Multiple Myeloma Models." Blood 120, no. 21 (2012): 5028. http://dx.doi.org/10.1182/blood.v120.21.5028.5028.

Full text

Abstract:

Abstract Abstract 5028 Multiple myeloma (MM) is a hematological malignancy of the bone marrow caused by the dysregulated proliferation of monoclonal antibody producing plasma cells. A hallmark feature of cancer is the ability to evade cell death signals induced by stress response cues. The Bcl-2 family of proteins regulates the intrinsic apoptosis pathways and consists of pro-apoptotic (Bax, Bak, Bad, Bim, Noxa, Puma) and pro-survival (Bcl-2, Bcl-xL, Mcl-1); the balance of which dictates the life or death status of MM tumor cells. Thus, there is a strong rationale to target members of the Bcl-

APA, Harvard, Vancouver, ISO, and other styles

14

Erickson-Miller, Connie L., Jennifer Kirchner, Kodandaram Pillarisetti, et al. "Eltrombopag Decreases Proliferation of Ovarian, Lung and Breast Tumor Cell Lines." Blood 114, no. 22 (2009): 2409. http://dx.doi.org/10.1182/blood.v114.22.2409.2409.

Full text

Abstract:

Abstract Abstract 2409 Poster Board II-386 Background: Eltrombopag (Promacta®) is a novel, oral thrombopoietin receptor (TpoR) agonist that interacts with the TpoR on bone marrow progenitors to stimulate megakaryocyte production, thus increasing platelet counts in thrombocytopenic patients. The effects of eltrombopag on the proliferation of solid tumor cell lines and the expression of thrombopoietin receptor (MPL, TpoR) on patient tumors is of interest given that chemotherapy can cause thrombocytopenia. Materials and methods: Proliferation was measured by Cell Titer Glo assay on 3 ovarian (OVC

APA, Harvard, Vancouver, ISO, and other styles

15

Prabhu, Varun V., Rohinton S. Tarapore, Mathew J. Garnett, et al. "Potent Anti-Leukemic Effects of Small Molecule ONC212, a Member of the Imipridone Class of Anti-Cancer Compounds." Blood 128, no. 22 (2016): 5133. http://dx.doi.org/10.1182/blood.v128.22.5133.5133.

Full text

Abstract:

Abstract ONC201, the founding member of the imipridone class of anti-cancer compounds, is a highly selective small molecule GPCR antagonist that is in Phase I/II advanced cancer clinical trials. In this study, we evaluated the anti-cancer effects of ONC212, an ONC201 analogue that possess the same unique core chemical structure shared by imipridones. The in vitro efficacy of ONC212 was assessed in the Genomics of Drug Sensitivity in Cancer collection of cell lines (>1,000 cell lines). Cell viability assays were performed to generate dose responses curves at concentrations from 78nM upto 20u

APA, Harvard, Vancouver, ISO, and other styles

16

Pramanik, Anik, Pan Xu, and Yifan Xu. "Equity Promotion in Public Transportation." Proceedings of the AAAI Conference on Artificial Intelligence 37, no. 10 (2023): 11890–98. http://dx.doi.org/10.1609/aaai.v37i10.26403.

Full text

Abstract:

There are many news articles reporting the obstacles confronting poverty-stricken households in access to public transits. These barriers create a great deal of inconveniences for these impoverished families and more importantly, they contribute a lot of social inequalities. A typical approach addressing the issue is to build more transport infrastructure to offer more opportunities to access the public transits especially for those deprived communities. Examples include adding more bus lines connecting needy residents to railways systems and extending existing bus lines to areas with low soci

APA, Harvard, Vancouver, ISO, and other styles

17

Maira Muniz Almeida, Wanda, and Eliane Guaraldo. "Urban Green Equity." Life Style 8, no. 2 (2022): 64–74. http://dx.doi.org/10.19141/2237-3756.lifestyle.v8.n2.p64-74.

Full text

Abstract:

The growing concern with the impacts of climate change and the fast urbanization of cities has led international policies to guide changes in attitudes by governments and civil society, directing effective models of sustainable governance aimed at environmental health and equal access for society environmental benefits. In this study, we seek to understand the evolution of research and scientific production on a topic of great relevance today – green equity. Through scientometric analysis based on a systematic literature review, we analyzed articles published in the period between 1992 and 202

APA, Harvard, Vancouver, ISO, and other styles

18

Thakurta, Anjan, Anita K. Gandhi, Michelle Waldman, et al. "Absence Of Mutation In Cereblon (CRBN) and DNA Damage Binding Protein 1 (DDB1) Genes In Myeloma Cells and Patients and Its Clinical Significance." Blood 122, no. 21 (2013): 3139. http://dx.doi.org/10.1182/blood.v122.21.3139.3139.

Full text

Abstract:

Abstract Background CRBN, a target of thalidomide and IMiDs® immunomodulatory agents lenalidomide (LEN) and pomalidomide (POM), is a component of the E3 ubiquitin cullin 4 ring ligase (CRL4) complex that also includes DDB1, Roc1, and Cul4. Two CRBN mutations have been reported in multiple myeloma (MM) patients: truncating mutation (Q99) and point mutation (R283K). One copy of the CRBN gene was shown to be deleted in the MM1S and MM1S.R cell lines. No DDB1 mutation has been described previously. Results We investigated the incidence of CRBN and DDB1 mutations by next-generation sequencing in 20

APA, Harvard, Vancouver, ISO, and other styles

19

Wang, Xiaomin, and Wenxin Zhang. "Efficiency and Spatial Equity Impacts of High-Speed Rail on the Central Plains Economic Region of China." Sustainability 11, no. 9 (2019): 2583. http://dx.doi.org/10.3390/su11092583.

Full text

Abstract:

Efficiency impacts can be assessed based on improvements in accessibility promoted by the high-speed rail (HSR) project, focusing mainly on major urban areas. Spatial equity impacts originate from changes in the distribution of accessibility levels observed across such cities. This study uses the weighted average travel time and coefficient of variation to explore the impact of HSR on efficiency and spatial equity within the Central Plains Economic Region (CPER) and to build an “efficiency-equity” model to identify optimal upgrading of conventional rail (CR) lines to improve the accessibility

APA, Harvard, Vancouver, ISO, and other styles

20

Arora, Shilpi, Kaylyn Williamson, Shruti Apte, et al. "EZH2 Inhibitors Are Broadly Efficacious in Multiple Myeloma As Single Agent and in Combination with Standard of Care Therapeutics." Blood 128, no. 22 (2016): 5672. http://dx.doi.org/10.1182/blood.v128.22.5672.5672.

Full text

Abstract:

Abstract Post-translational modifications of the histone proteins play a key role in regulating processes that require access to DNA. Specifically, methylation of lysine 27 on histone 3 (H3K27) is intimately linked with transcriptional repression. EZH2, a histone lysine methyl transferase is the catalytic component of the PRC2 complex, which catalyzes H3K27 methylation. EZH2 dysregulation has been observed in different malignancies and inhibition of its catalytic activity has emerged as a novel therapeutic approach to treat human cancers. Potent, selective and reversible EZH2 small molecule in

APA, Harvard, Vancouver, ISO, and other styles

21

Ahsan, Aarif, Ann Polonskaia, Chih-Chao Hsu, et al. "Super-Enhancer Driven Regulation of CKS1B in Multiple Myeloma: Implications in Mediating Response to BET Inhibitor and Celmod Agent Combination." Blood 138, Supplement 1 (2021): 2658. http://dx.doi.org/10.1182/blood-2021-150641.

Full text

Abstract:

Abstract Introduction: The Myeloma Genome Project (MGP) characterized the genomic landscape of patients with newly diagnosed multiple myeloma (NDMM) (Walker BA, et al. Blood 2018; 132[6]:587-597). Using a multi-omics unsupervised clustering approach, 12 molecularly-defined disease segments were identified (Ortiz M, et al. Blood 2018; 132[suppl 1]:3165). Here, we performed experimental validation of CDC28 Protein Kinase Regulatory Subunit 1B (CSK1B) that was identified as a putative target from the disease segment with poorest clinical outcome. CKS1B was selected for in-depth validation due to

APA, Harvard, Vancouver, ISO, and other styles

22

Peng, Mao Yu, Yasmin Abaza, Martina Mcdermott, Monica Mead, Dennis J. Slamon, and Sarah Larson. "Activity of Carfilzomib (CFZ) in Acute Myeloid Leukemia (AML) As a Single Agent and in Novel Combinations." Blood 136, Supplement 1 (2020): 6–7. http://dx.doi.org/10.1182/blood-2020-141459.

Full text

Abstract:

Background:Recent advances in targeted therapy have expanded the available therapeutic optionsfor patients with AML. However, many patients still have suboptimal outcomes, particularly in the relapsed/refractory setting, underscoring the need for novel therapeutic strategies. Proteasome inhibitors (PIs), such as bortezomib, exhibit antitumor activity in AML through inhibition of the nuclear factor κB pathway and induction of apoptosis. CFZ, a second-generation PI, has preferential preclinical activity in AML compared to bortezomib making it an agent of interest in AML therapy. Here we assessed

APA, Harvard, Vancouver, ISO, and other styles

23

Chen, Janice, Christopher L. Brooks, Peter McDonald, et al. "SL-801, a Novel, Reversible Inhibitor of Exportin-1 (XPO1) / Chromosome Region Maintenance-1 (CRM1) with Broad and Potent Anti-Cancer Activity." Blood 126, no. 23 (2015): 4433. http://dx.doi.org/10.1182/blood.v126.23.4433.4433.

Full text

Abstract:

Abstract XPO1/CRM1, the principal nuclear export protein in eukaryotic cells, is required for the nuclear-cytoplasmic transport of both proteins and RNAs. Overexpression of XPO1 is reported in many cancers, causing dysregulated protein localization, aberrant cell proliferation, and resistance to apoptosis, and is associated with aggressive characteristics and poor patient outcome. Recent work has revealed XPO1 to be a clinically relevant target, and nuclear export inhibitors have emerged as a new class of anti-cancer agents with clinical activity in multiple hematologic and solid malignancies.

APA, Harvard, Vancouver, ISO, and other styles

24

Liu, Yang. "The Sources of Debt Matter Too." Journal of Financial and Quantitative Analysis 41, no. 2 (2006): 295–316. http://dx.doi.org/10.1017/s0022109000002076.

Full text

Abstract:

AbstractThis paper examines the effects of different types of private debt on firm cash balances, equity risk, and investment. Firms with more bank loans have more cash and investment, but lower equity risk. Firms with more nonbank private debt have more cash, lower equity risk, and less investment. Firms with more unused credit lines have less cash and lower equity risk, but greater investment. Results suggest that financial intermediaries' monitoring intensity increases with loan size. Depending on type, private debt mitigates information asymmetry or asset substitution, or both. Deposit rel

APA, Harvard, Vancouver, ISO, and other styles

25

Zhang, Yue, Julie Parmentier, Zhongwu Lai, et al. "Spleen Tyrosine Kinase Inhibitor Fostamatinib Blocks B Cell Receptor Signaling and Reduces Viability of BCR Subtype Diffuse Large B Cell Lymphoma." Blood 120, no. 21 (2012): 3720. http://dx.doi.org/10.1182/blood.v120.21.3720.3720.

Full text

Abstract:

Abstract Abstract 3720 Spleen tyrosine kinase (SYK) plays a key role in B cell receptor mediated survival in certain B cell malignancies including Diffuse Large B Cell Lymphoma (DLBCL). Therefore, targeting SYK represents an emerging therapeutic approach for the treatment of DLBCL. Indeed, fostamatinib, an orally available SYK inhibitor, has shown promising clinical activity in non-Hodgkin lymphoma (Friedberg et al. 2010 Blood 115: 2578). However, the overall response rate for novel targeted agents in unselected relapsed refractory DLBCL patients remains 25–30%, highlighting the opportunity fo

APA, Harvard, Vancouver, ISO, and other styles

26

Lopez-Girona, Antonia, Courtney G. Havens, Gang Lu, et al. "CC-92480 Is a Novel Cereblon E3 Ligase Modulator with Enhanced Tumoricidal and Immunomodulatory Activity Against Sensitive and Resistant Multiple Myeloma Cells." Blood 134, Supplement_1 (2019): 1812. http://dx.doi.org/10.1182/blood-2019-124338.

Full text

Abstract:

Lenalidomide- and pomalidomide-based therapies are effective drugs in the treatment of patients with multiple myeloma (MM), however most patients with MM eventually relapse or become resistant. CC-92480, a novel cereblon (CRBN) E3 ligase modulator (CELMoD) with multiple activities including potent immunomodulation and single-agent antiproliferative effects, is being investigated in a phase 1 clinical trial (CC-92480-MM-001; NCT03374085) for patients with relapsed/refractory MM (RRMM). The present study investigates the preclinical data and mechanism of action of CC-92480 in MM models. CELMoD a

APA, Harvard, Vancouver, ISO, and other styles

27

Rivera, Victor M., Justin R. Pritchard, Francois Gonzalvez, Theresa Baker, Joseph M. Gozgit, and Graeme Hodgson. "Comparative TKI Profiling Analyses to Explore Potential Mechanisms of Ponatinib-Associated Arterial Thrombotic Events." Blood 124, no. 21 (2014): 1783. http://dx.doi.org/10.1182/blood.v124.21.1783.1783.

Full text

Abstract:

Abstract Background: Ponatinib is a potent pan-BCR-ABL tyrosine kinase inhibitor (TKI) indicated for patients with T315I positive or treatment-refractory CML and Ph+ ALL. To develop hypotheses regarding molecular and cellular targets of ponatinib that could contribute to arterial thrombotic events observed in some patients we are undertaking a broad comparative profiling analysis of ponatinib and other TKIs. Methods: Cellular activities of ponatinib and additional BCR-ABL (imatinib, nilotinib, dasatinib, bosutinib) and VEGFR2/multi-targeted (sunitinib, regorafenib) TKIs were examined in panels

APA, Harvard, Vancouver, ISO, and other styles

28

Gandhi, Anita K., Herve Avet-Loiseau, Michelle Waldman, et al. "Detection and Quantification of Cereblon Protein and mRNA in Multiple Myeloma Cell Lines and Primary CD138+multiple Myeloma Cells." Blood 120, no. 21 (2012): 4043. http://dx.doi.org/10.1182/blood.v120.21.4043.4043.

Full text

Abstract:

Abstract Abstract 4043 Background: Cereblon (CRBN), a component of the DDB1-CUL4A-Roc1 ubiquitin ligase complex, has been identified as a target of the immunomodulatory agents thalidomide, lenalidomide, and pomalidomide (Lopez-Girona et al. Leukemia. 2012; Zhu et al. Blood. 2011; Ito et al. Science. 2010.). CRBN binding by these agents mediates their anti-proliferative effects in multiple myeloma (MM) cells (Lopez-Girona et al. Leukemia. 2012; Zhu et al. Blood. 2011). However, the role of CRBN quantification as a marker for disease responsiveness or resistance to these drugs remains to be full

APA, Harvard, Vancouver, ISO, and other styles

29

Fernández, Leonor, and Peter Shorett. "Lessons in Equity From the Front Lines of COVID-19 Vaccination." JAMA Health Forum 2, no. 4 (2021): e210612. http://dx.doi.org/10.1001/jamahealthforum.2021.0612.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Turner, PG. "Fault Lines In Equity Edited by Jamie Glister and Pauline Ridge." Oxford University Commonwealth Law Journal 12, no. 2 (2012): 393–97. http://dx.doi.org/10.1080/14729342.2012.11421351.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Li, Lingna, Wenyong Tong, Megan Lau, et al. "Preclinical Development of an Anti-CD38 Antibody-Drug Conjugate for Treatment of Hematological Malignancies." Blood 134, Supplement_1 (2019): 5621. http://dx.doi.org/10.1182/blood-2019-132062.

Full text

Abstract:

CD38 is a validated target for the treatment of multiple myeloma (MM). Daratumumab (Darzalex®), an anti-CD38 monoclonal antibody (mAb), has shown great clinical efficacy and has been approved for multiple myeloma treatment. However, both primary refractoriness and development of resistance to daratumumab therapy have been reported. Based on the therapeutic benefits of this CD38 antibody, we developed a CD38-targeting antibody-drug conjugate (ADC), employing a fully human anti-CD38 antibody STI-6129, identified from Sorrento's G-MAB® antibody library, and proprietary linker-toxin technology. Th

APA, Harvard, Vancouver, ISO, and other styles

32

Lyons, Torrey, and Dong-ah Choi. "Transit Economic Equity Index: Developing a Comprehensive Measure of Transit Service Equity." Transportation Research Record: Journal of the Transportation Research Board 2675, no. 3 (2021): 288–300. http://dx.doi.org/10.1177/0361198120970529.

Full text

Abstract:

In this study an index is developed called the Transit Economic Equity Index, to enable quantitative assessment of transit service equity. The index measures convenience of travel for work trips for advantaged and disadvantaged populations, based on travel speed, using a multimodal network that includes transit lines, stop locations, transit schedules, and pedestrian connections via the street network. Non-peak hour service is compared with peak hour service to determine the degree to which operating resources are concentrated in times that might have greater benefits to advantaged populations

APA, Harvard, Vancouver, ISO, and other styles

33

Wang, Beatrice T., Thomas J. Matthew, Ling Wang, et al. "The Anti-Tumor Activity of Igm-8444, an Agonistic Death Receptor 5 (DR5) IgM Antibody, Is Sensitized in Combination with Chemotherapy and Bcl-2 Inhibitors in NHL and AML." Blood 136, Supplement 1 (2020): 43–44. http://dx.doi.org/10.1182/blood-2020-141449.

Full text

Abstract:

Background: Death receptor 5 (DR5) is a member of the tumor necrosis factor (TNF) receptor superfamily that multimerizes when bound to its ligand, TNF-related apoptosis inducing ligand (TRAIL), to activate the extrinsic apoptotic pathway. DR5 is broadly expressed on solid and hematologic cancers and has been targeted with both recombinant TRAIL and agonistic antibodies in the clinic. However, these therapeutics have been unsuccessful due to lack of efficacy or hepatotoxicity. We have developed IGM-8444, a pentameric IgM with 10 binding sites specific for DR5, that multimerizes DR5 to selective

APA, Harvard, Vancouver, ISO, and other styles

34

Bates, Jamie, Saritha Kusam, Stacey Tannheimer, et al. "Combination of the BET Inhibitor GS-5829 and a BCL2 Inhibitor Resulted in Broader Activity in DLBCL and MCL Cell Lines." Blood 128, no. 22 (2016): 5104. http://dx.doi.org/10.1182/blood.v128.22.5104.5104.

Full text

Abstract:

Abstract Introduction: GS-5829 is a potent and selective inhibitor of the bromodomain and extra-terminal (BET) family of proteins. BET proteins regulate the transcription of key oncogenes including MYC, resulting in cancer cell growth (Yang Z. et. al. Mol Cell Biol 2008; LeRoy G. et. al. Mol Cell 2008). Diffuse large B-cell lymphoma (DLBCL) is a diverse and genetically heterogeneous subtype of non-Hodgkin's lymphoma (NHL) (Lenz G. et. al. N Engl J Med 2010). Lymphomas harboring translocation of both MYC and BCL2, the so called "double hit" lymphoma, have a poor prognosis (Li S. et. al. Mod Pat

APA, Harvard, Vancouver, ISO, and other styles

35

Cojocari, Dan, Sha Jin, Julie J. Purkal, et al. "5-Azacytidine Induces NOXA and PUMA Expression to Prime AML Cells for Venetoclax-Mediated Apoptosis." Blood 132, Supplement 1 (2018): 2644. http://dx.doi.org/10.1182/blood-2018-99-111985.

Full text

Abstract:

Abstract Acute myeloid leukemia (AML) is a clonal hematologic malignancy characterized by genomic heterogeneity and epigenetic changes, including aberrant DNA hypermethylation. Phase-Ib clinical data in relapsed/refractory AML patients indicate that combining venetoclax with the hypomethylating agents (HMAs) 5-azacitidine (5-Aza) or decitabine results in an overall response (OR) of 62% (DiNardo et al. 2018) compared to the historical OR of 28-29% with HMAs treatment alone (Kantarjian et al. 2013; Dombret et al. 2015). Subsequently, a randomized phase-III clinical trial was initiated to evaluat

APA, Harvard, Vancouver, ISO, and other styles

36

Pinho, Pedro, Helen Kylefjord, Vilma Rraklli, et al. "Protides of 5-Fluorotroxacitabine Display Potent Anti-Proliferative Properties and Circumvent Deoxycytidine Kinase-Mediated Resistance Associated with Cytotoxic Cytidine Analogues; A Novel Approach for Acute Myeloid Leukemia." Blood 132, Supplement 1 (2018): 3497. http://dx.doi.org/10.1182/blood-2018-99-114440.

Full text

Abstract:

Abstract The cytotoxic nucleoside cytarabine forms the backbone of AML induction and consolidation therapies, but is associated with severe toxicities that preclude its use in patients unable to tolerate aggressive chemotherapy. Options for patients that do not respond to cytarabine, or relapse post-treatment, are limited. Elderly patients and those with relapsed/refractory AML would particularly benefit from the availability of new agents to develop treatment regimens that provide increased efficacy and tolerability compared to cytarabine, and that have a decreased susceptibility to mechanism

APA, Harvard, Vancouver, ISO, and other styles

37

Klatt, Martin G., Zhiyuan Yang, Jianying Liu, et al. "A TCR Mimic Antibody-Directed CAR T Cell Specific for Intracellular NDC80 Is Broadly Cancer Reactive and Displays High Activity Against Hematological Malignancies." Blood 136, Supplement 1 (2020): 20–21. http://dx.doi.org/10.1182/blood-2020-140179.

Full text

Abstract:

Chimeric antigen receptor (CAR) T cells represent a novel class of FDA-approved drugs with high efficacy against refractory B cell derived malignancies and potentially other cancer types. However, target selection for CAR T cell therapy remains challenging as cell surface proteins are not cancer-specific and therefore often not adaptable for CAR T cell therapy. In contrast, many intracellular proteins can be highly tumor specific and are targetable after proteasomal degradation and presentation on human leukocyte antigen (HLA) complexes recognized by T cell receptor mimic antibodies. This clas

APA, Harvard, Vancouver, ISO, and other styles

38

Totman, Jennifer, Dorothy Brach, Vinny Motwani, et al. "Pharmacologic Inhibition of the Histone Methyltransferase SETD2 with EZM0414 As a Novel Therapeutic Strategy in Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma." Blood 138, Supplement 1 (2021): 1142. http://dx.doi.org/10.1182/blood-2021-151147.

Full text

Abstract:

Abstract Introduction: SETD2 is the only known histone methyltransferase (HMT) capable of catalyzing H3K36 trimethylation (H3K36me3) in vivo. It plays an important role in several biological processes including B cell development and maturation, leading to the hypothesis that SETD2 inhibition in these settings could provide anti-tumor effects. The normal process of B cell development/maturation renders B cells susceptible to genetic vulnerabilities that can result in a dysregulated epigenome and tumorigenesis, including in multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL). For ex

APA, Harvard, Vancouver, ISO, and other styles

39

Cheung, Kam, Gloria Juan, William Wayne, et al. "AMG 900, a Potent and Highly Selective Aurora Kinase Inhibitor Shows Promising Preclinical Activity Against Acute Myeloid Leukemia Cell Lines In Vitro and In Vivo." Blood 122, no. 21 (2013): 3823. http://dx.doi.org/10.1182/blood.v122.21.3823.3823.

Full text

Abstract:

Abstract Aurora kinases A and B play essential roles in multiple stages of mitosis and are frequently overexpressed in a subset of human cancers, including acute myeloid leukemia (AML) (Ikezoe T et al, 2007). AMG 900, a potent and highly selective small molecule inhibitor of aurora kinases, is currently in Phase 1 clinical testing in adult patients with AML. In this study, we report the preclinical effects of AMG 900 in AML cell lines. We show that AMG 900 inhibits the phosphorylation of Histone H3 on serine-10 (a proximal substrate of aurora-B) leading to aborted cell division, apoptosis and/

APA, Harvard, Vancouver, ISO, and other styles

40

Chen, Jun, Sha Jin, Paul Tapang, et al. "CDK9 Inhibition Reverses Resistance to ABT-199 (GDC-0199) By Down-Regulating MCL-1." Blood 124, no. 21 (2014): 2161. http://dx.doi.org/10.1182/blood.v124.21.2161.2161.

Full text

Abstract:

Abstract All authors are employees of AbbVie and participated in the design, conduct, and interpretation of these studies. AbbVie and Genentech provided financial support for these studies and participated in the review and approval of this publication. The BCL-2-selective inhibitor ABT-199 has demonstrated efficacy in numerous preclinical models of hematologic malignancies without causing thrombocytopenia, a dose-limiting toxicity associated with the BCL-2/BCL-XL inhibitor navitoclax (Souers et al. 2013. Nat. Med. 19, 202-208). ABT-199 has also demonstrated clinical activity in chronic lympho

APA, Harvard, Vancouver, ISO, and other styles

41

Penebre, Elayne, Kristy G. Kuplast, Christina R. Majer, et al. "Identification of a First-in-Class PRMT5 Inhibitor with Potent in Vitro and in Vivo Activity in Preclinical Models of Mantle Cell Lymphoma." Blood 124, no. 21 (2014): 438. http://dx.doi.org/10.1182/blood.v124.21.438.438.

Full text

Abstract:

Abstract Protein Arginine Methyltransferase-5 (PRMT5) has been reported to play a role in multiple diverse cellular processes including tumorigenesis. Overexpression of PRMT5 has been demonstrated in cell lines and primary patient samples derived from lymphomas, particularly Mantle Cell Lymphoma (MCL). Furthermore, knockdown of PRMT5 expression inhibits the proliferation of MCL cell lines. The mechanisms behind the oncogenic potential of PRMT5 are unclear, but the protein has been postulated to regulate processes such as cell death, cell cycle progression, and RNA processing through the dimeth

APA, Harvard, Vancouver, ISO, and other styles

42

Rychak, Emily, Derek Mendy, Karen Miller, et al. "The Novel mTOR Kinase Inhibitor CC-223 Demonstrates Significant Activity In In Vitro Models Of Multiple Myeloma (MM), Both As a Single Agent and In Combination With The Approved Agents, Dexamethasone, Lenalidomide and Pomalidomide." Blood 122, no. 21 (2013): 3160. http://dx.doi.org/10.1182/blood.v122.21.3160.3160.

Full text

Abstract:

Abstract Over expression of the PI3 kinase/mTOR/AKT pathway has been well documented in MM patient biopsies and human MM cell lines, suggesting this pathway plays a key role in the survival and proliferation of malignant plasma cells. Rapamycin and the rapalogs are allosteric inhibitors of the mTORC1 complex (consisting of mTOR, raptor, mLST8 and PRAS40), inducing mainly cytostatic effects but not cell death. Inhibition of mTORC1 prevents a negative feedback loop to the mTORC2 complex (consisting of mTOR, Rictor, mLST8 and Sin 1) leading to the phosphorylation of AKT. Phosphorylated AKT is a k

APA, Harvard, Vancouver, ISO, and other styles

43

Weyland, Kurt. "“Growth With Equity” in Chile's New Democracy?" Latin American Research Review 32, no. 1 (1997): 37–68. http://dx.doi.org/10.1017/s0023879100037651.

Full text

Abstract:

The new democracy in Chile provides an interesting test case for two influential lines of thinking on Latin American political economy. Both these perspectives have claimed that the recently installed civilian regimes would find it exceedingly difficult to effect equity-enhancing change. One hypothesis has stressed the impediments posed by a capitalist free-market system to measures favoring the poor. The other has emphasized the obstacles presented by a transition to democracy that avoids a rupture with the preceding conservative dictatorship. Because the democratic government led by Patricio

APA, Harvard, Vancouver, ISO, and other styles

44

McElligott, David L., Edward Kesicki, Kannan Karukarichi, et al. "Development of Inhibitors of PIP4K2 As a Treatment for Patients with Hematologic Malignancies." Blood 132, Supplement 1 (2018): 213. http://dx.doi.org/10.1182/blood-2018-99-118355.

Full text

Abstract:

Abstract Phosphoinositide signaling is central to many cellular processes including the cell survival pathway known as autophagy. While there is evidence that autophagy can suppress tumorigenesis under certain circumstances, there is increasingly abundant evidence that autophagy promotes tumorigenesis and tumor cell survival in solid tumors and hematologic malignancies. Autophagy is a complex process that has evolved to promote survival of cells under a variety of stress or nutrient starvation conditions. There are a multitude of molecules and structures involved in initiating, promoting, and

APA, Harvard, Vancouver, ISO, and other styles

45

Csibi, Fred, Nan Ji, Bin Yang, et al. "Small Molecule-Induced, Selective STAT3 Degradation Leads to Anti-Tumor Activity in STAT3-Dependent Heme Malignancies." Blood 134, Supplement_1 (2019): 3803. http://dx.doi.org/10.1182/blood-2019-128981.

Full text

Abstract:

Targeted protein degradation mediated by small molecule degraders represents a new and exciting therapeutic modality to target difficult-to-drug oncogenic proteins including transcription factors. These molecules bind to both the target protein and an E3 ligase, enabling the formation of a ternary complex that leads to ubiquitination and subsequent degradation of the target protein by the proteasome. STAT3 (signal transducers and activators of transcription 3) is a transcription factor and a member of the STAT protein family. In response to cytokines and growth factors, STAT3 is phosphorylated

APA, Harvard, Vancouver, ISO, and other styles

46

Fiore, Christopher, Michael R. McKeown, Emily Lee, Matthew L. Eaton, and Christian C. Fritz. "SY1425 (tamibarotene) Induces Profound Transcriptional Changes in AML Tumors with High Retinoic Acid Receptor Alpha." Blood 128, no. 22 (2016): 1523. http://dx.doi.org/10.1182/blood.v128.22.1523.1523.

Full text

Abstract:

Abstract Retinoic acid receptor alpha (RARα) regulates myeloid differentiation and proliferation through the regulation of specific sets of genes. When unbound by a ligand, RARα is a repressive transcription factor while in its ligand-bound state it functions as a transcriptional activator. Previously, blast cells from a subset of individuals with non-APL AML were found to have a super-enhancer (SE), as revealed by H3K27 acetyl ChIP-Seq, associated with the RARA locus (hereafter called RARA-high), suggesting that tumor cell proliferation may have a dependency on RARA that can be exploited for

APA, Harvard, Vancouver, ISO, and other styles

47

Ding, Bei Bei, John Dixon Gray, Irina Krapf, et al. "Development of a Genetically-Engineered Allogeneic Anti-CD38 T Cell Therapy Utilizing a Novel Antigen Receptor Structure." Blood 134, Supplement_1 (2019): 4444. http://dx.doi.org/10.1182/blood-2019-131586.

Full text

Abstract:

Background: Autologous Chimeric Antigen Receptor (CAR) T cell therapy has shown great promise as a treatment modality for a variety of hematological malignancies. But autologous cell therapies still face several practical hurdles, including reliance on patient immune cells and manufacturing difficulties. Sorrento has pioneered an allogeneic T cell therapy approach utilizing genetic engineering of donor-derived T cells to express a Dimeric Antigen Receptor (DAR). The first DAR-T cell therapy being developed is targeted against CD38, a clinically-validated antigen in multiple myeloma. Preclinica

APA, Harvard, Vancouver, ISO, and other styles

48

Lowe, Eric, Andrea R. Fan, Jing Jiang, et al. "Blocking Protein Secretion with Novel Small Molecule Inhibitors of Sec61 Represents a Potential Treatment Strategy Against Hematologic Malignancies." Blood 134, Supplement_1 (2019): 408. http://dx.doi.org/10.1182/blood-2019-123782.

Full text

Abstract:

Secreted and membrane proteins play key roles in cancer development, including as autocrine growth factors, receptors in oncogenic signaling cascades, and checkpoints in immune system evasion. The biogenesis of most secreted and transmembrane proteins involves cotranslational translocation of nascent polypeptides ("clients") into the endoplasmic reticulum (ER) through the Sec61 translocon. Multiple inhibitors of protein secretion have been described that target Sec61 and have antitumor activity but lack adequate pharmaceutical properties or tolerability to be studied clinically. Here we descri

APA, Harvard, Vancouver, ISO, and other styles

49

Kekre, Rohan, and Moritz Lenel. "The High-Frequency Effects of Dollar Swap Lines." American Economic Review: Insights 7, no. 1 (2025): 107–23. https://doi.org/10.1257/aeri.20230667.

Full text

Abstract:

We study the effects of dollar swap lines using high-frequency responses in asset prices around policy announcements. News about expanded dollar swap lines causes a reduction in liquidity premia, compression of deviations from covered interest parity, and depreciation of the dollar. Equity prices rise and the VIX falls, while the response of long-term government bond prices is mixed. The cross section of high-frequency responses implies that swap lines affect the dollar factor or the price of risk. Our findings are qualitatively consistent with models relating the supply of dollar liquidity to

APA, Harvard, Vancouver, ISO, and other styles

50

Aryal, Neeraj K., Anjana Sundarrajan, Scott Boiko, et al. "Elongator Complex Regulates MCL1 Dependency Via IRE1-XBP1 Axis of the ER Stress Response Pathway in Multiple Myeloma." Blood 138, Supplement 1 (2021): 2275. http://dx.doi.org/10.1182/blood-2021-151194.

Full text

Abstract:

Abstract Evasion of apoptosis is a hallmark of cancer wherein overexpression and amplification of pro-survival BCL2-family genes like MCL1 is a common observation. MCL1 is frequently amplified in many hematological cancers like Multiple Myeloma (MM) that depend on it for survival. BH3 mimetic drugs, like the BCL2-specific inhibitor Venetoclax, have been successfully used in the clinic to treat certain cancers, and MCL1-selective inhibitors are currently in clinical development. While inhibition of MCL1 displays promising preclinical activity, many cancer models display acquired or intrinsic re

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!